An observational study in Chemotherapy Effect, Chemotherapeutic Toxicity and Lower Urinary Tract Symptoms, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Ludwig-Maximilians - University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Urinary Bladder, Overactive with a site in Germany — 1 open to participants now, 1 under way, none of them phase 3. Urinary Bladder, Overactive · Germany.
Among the 48 studies in Urinary Bladder, Overactive with a site in Germany, this one is the only one that started in 2023, is one of 4 observational ones, and was the 48th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →1 of the 48 studies in Urinary Bladder, Overactive with a site in Germany is open now.
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Median enrollment 549 across the 42 interventional studies, 358 across the 4 observational. Of the 46 that completed or were terminated, 27 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 48 have an industry lead sponsor. The 10 most frequent:
Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Ludwig-Maximilians - University of Munich has 2 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 48 studies in Urinary Bladder, Overactive with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With this prospective, observational study, we would like to investigate the effect of instillation therapy using BCG or mitomycin C on short- and long-term irritative and obstructive lower urinary tract symptoms using validated questionnaires. The study will objectify the lower urinary tract symptoms and thereby provide better recommendations for therapy with mitomycin C or BCG.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
This study's planned enrollment of 60 is below the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Browse Urinary Bladder, Overactive studies →Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Compared within Urinary Bladder, Overactive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lower Urinary Tract Symptoms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with urinary bladder carcinoma requiring instillation therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer
Other: Validated questionnaires
All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer
Other: Validated questionnaires
BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Effect of instillation therapy on quality of life
Quality of life will be measured with validated questionnaires such as the ICIQ-OABqol
Time frame: During the study period approximately 12 months
Effect of instillation therapy on sexuality
Sexuality will be measured with validated questionnaires such as the IIEF-EF (men) and the FSFI (women)
Time frame: During the study period approximately 12 months
Effect of instillation therapy on lower urinary tract symptoms
Lower urinary tract symptoms will be measured with validated questionnaires such as the BPIC-SS, the ICIQ-MLUTS (men) and the ICIQ-FLUTS (women)
Time frame: During the study period approximately 12 months
Complications during instillation therapy
The frequency of all complications will be measured and will be subsequently classified based on the Clavien-Dindo classification
Time frame: During the study period approximately 12 months
Discontinuation rate of instillation therapy
Time frame: During the study period approximately 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Apr 2025, 24 months after the start.
Of 46 non-industry observational studies under Urinary Bladder, Overactive, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 59 studies reached it within 32 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ludwig-Maximilians - University of Munich →